Explore

Trendline Trendline
Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results

Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results

Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Trendline Trendline
Sarepta, Amylyx, and Neumora Prepare for Key Milestones Amidst Q1 Earnings

Sarepta, Amylyx, and Neumora Prepare for Key Milestones Amidst Q1 Earnings

Sarepta, Amylyx, and Neumora Prepare for Key Milestones Amidst Q1 Earnings
Trendline Trendline
Sarepta, Amylyx, and Neumora Anticipate Key Developments Amidst Q1 Earnings

Sarepta, Amylyx, and Neumora Anticipate Key Developments Amidst Q1 Earnings

Sarepta, Amylyx, and Neumora Anticipate Key Developments Amidst Q1 Earnings
Trendline Trendline
SAB Biotherapeutics Enters $36 Million Manufacturing Agreement for SAB-142 with Emergent BioSolutions

SAB Biotherapeutics Enters $36 Million Manufacturing Agreement for SAB-142 with Emergent BioSolutions

SAB Biotherapeutics Enters $36 Million Manufacturing Agreement for SAB-142 with Emergent BioSolutions
Trendline Trendline
Supernus Pharmaceuticals Reports Q1 CY2026 Sales Surpassing Expectations Despite Earnings Miss

Supernus Pharmaceuticals Reports Q1 CY2026 Sales Surpassing Expectations Despite Earnings Miss

Supernus Pharmaceuticals Reports Q1 CY2026 Sales Surpassing Expectations Despite Earnings Miss
Trendline Trendline
Veracyte Reports Strong Revenue Growth in First Quarter 2026

Veracyte Reports Strong Revenue Growth in First Quarter 2026

Veracyte Reports Strong Revenue Growth in First Quarter 2026
Trendline Trendline
LEO Pharma Reports 9% Revenue Growth in Q1 2026, Expands Innovation Pipeline

LEO Pharma Reports 9% Revenue Growth in Q1 2026, Expands Innovation Pipeline

LEO Pharma Reports 9% Revenue Growth in Q1 2026, Expands Innovation Pipeline
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Expansion Plans

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Expansion Plans

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Expansion Plans
Trendline Trendline
GeneDx Reports Q1 2026 Financial Results and Updates Outlook

GeneDx Reports Q1 2026 Financial Results and Updates Outlook

GeneDx Reports Q1 2026 Financial Results and Updates Outlook
Trendline Trendline
ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates
Trendline Trendline
Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark

Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark

Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark